Senior Scientist

Overview

Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency.

Responsibilities

Position Summary: The Senior Scientist, Analytical Development will be responsible for leading development of flowcytometry-based assays for release and characterization of engineered T-cell products and analytics for process understanding. The successful candidate will be responsible for leading a group within Analytical Development and mentoring scientists, hands-on assay development and driving projects in close collaboration across TechOps and research.

In this role you will work closely with other members of the analytical development team to develop strategy, conduct experiments, develop test methods, and assist in the tech transfer of analytical methodologies into a GMP manufacturing and QC testing facility. The successful candidate will have expertise in flowcytometry based assay development, experience with analytical testing methodologies and an understanding of the technological requirements to execute on testing and characterization needs of a cellular therapy company.

Responsibilities (Essential Functions)

• Design, develop, execute, and document flowcytometry analytical methods for release testing and to study processes for production of T cell therapies
• Critically analyzes, interprets complex data drawing appropriate conclusions
• Support product characterization activities, including comparability assessments in support of product life cycle management
• Act as a subject matter expert in providing analytical and data interpretation both internally and externally
• Partner in the transfer of qualified assays to QC, and support assay validation and investigations
• Responsible for completion of assignments that have an impact on functional goals
• Develop and deliver scientific presentations, prepare clear and concise technical reports, participate in project teams, and contribute to regulatory filings, as needed
• Participate in the evaluation of new analytical technologies and their implementation
• Revise, review, and author assay standard operating procedures
• Contribute to building a culture that encourages continuous learning, improvement, and innovation, and encourages team members to expand their technical skill base

Qualifications

Education:

• Must have a PhD in cell biology, immunology or related field with at least six years’ relevant industry experience or an MS with at least 11 years of relevant industry experience

Preferred Experience & Skills:

• A minimum of 10 years of extensive experience in developing flow-based assays
• Well versed with various flowcytometers such as MACSQuant, BD Lyric and Cytek Aurora.
• Experience in a wide variety of analytical techniques such as cytotoxicity assays, flow cytometry, cytokine release assays, cell counting and other applicable methods is a plus
• Prior experience of leading and managing scientific teams
• Experience in analytical development, cGMP QC testing and implementation of new technologies in a regulated environment
• Experience with assessment of new technologies in a fast-paced, learning organization; preferably in a cross-functional setting where impact of new technologies is evaluated across research, development and commercial organizations
• Prior experience in cell therapy development preferred
• Must have excellent oral and written communication skills
• Proven ability to work independently and collaboratively among cross-functional teams
• Ability to work efficiently, prioritize workflow, meet deadlines and balance competing priorities
• Excellent analytical skills and technical expertise

Compensation and Benefits

Salary: The salary range for this position is $180,000 to $210,000, annually, with the opportunity to earn an annual bonus. The salary range is an estimate, and the actual salary may vary based on Lyell’s compensation practices and an applicant’s qualifications and experience. Employees are also eligible to participate in Lyell’s Equity Incentive Plan.

Benefits: Our Employee Benefits program is extensive and includes subsidized medical, dental and vision plans from your first day of employment, FSA, Company provided Life and AD&D Insurance as well as STD and LTD Insurance, ESPP, a 401(k) Plan with Company match, mass transit commuter benefits, cell phone reimbursement and a range of supplemental benefits that you may choose to elect. Our paid time-off benefits currently include 18 days’ vacation, 9 day’s sick leave, 8 observed holidays as well as a floating holiday. We also have a summer and a winter office shutdown.

Equal Opportunity

Lyell is an equal opportunity employer and does not discriminate on the basis of race, color, citizenship status, national origin, ancestry, sex, sexual orientation, age, religion, creed, physical or mental disability, medical condition, marital status, veteran status or any other characteristics protected under applicable federal, state and local laws.

Voluntary Self-Identification

For government reporting purposes, we ask candidates to respond to the below self-identification survey. Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiring process or thereafter. Any information that you do provide will be recorded and maintained in a confidential file. As set forth in Lyell Immunopharma’s Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law.

Voluntary Self-Identification of Disability

Form CC-305

Page 1 of 1

OMB Control Number

Expires 04/30/2026

Why are you being asked to complete this form? We are a federal contractor or subcontractor. The law requires us to provide equal employment opportunity to qualified people with disabilities. We have a goal of having at least 7% of our workers as people with disabilities. The law says we must measure our progress towards this goal. To do this, we must ask applicants and employees if they have a disability or have ever had one. People can become disabled, so we need to ask this question at least every five years.

Completing this form is voluntary, and we hope that you will choose to do so. Your answer is confidential. No one who makes hiring decisions will see it. Your decision to complete the form and your answer will not harm you in any way. If you want to learn more about the law or this form, visit the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) website at .

#J-18808-Ljbffr